2018 Asthma Pipeline Assessment and Insights - ResearchAndMarkets.com

DUBLIN--()--The "Asthma: Pipeline Assessment and Insights" report has been added to ResearchAndMarkets.com's offering.

Asthma: Pipeline Assessment and Insights report delivers an in-depth understanding of the disease, highlights all the pipeline products in different phases of development for the disease including the Suspended products and outlines in detail the drug profiles of key Pipeline therapies in the disease area.

Pipeline Covered:

NDA/BLA Filed

Phase III Pipeline

Phase II Pipeline

Phase I Pipeline

Preclinical Pipeline

Discovery Pipeline

Suspended and Terminated products

Pipeline analysis by Mechanism of Action

Pipeline Analysis by Novelty of Mechanism of Action

Key Topics Covered:

1 Tables & Figures

2 Asthma Disease

2.1 Disease Overview

3 Pipeline Assessment

3.1 Overview

3.2 Strategic Review of the Pipeline

3.3 Pipeline analysis by Phases of Development

3.4 Pipeline Analysis by Mechanism of Action

3.5 Pipeline Analysis by Novelty of Mechanism of Action

3.6 Suspended and Terminated products

3.7 Asthma - Promising Therapies in Pipeline

4 Appendix

Companies Mentioned

  • Boehringer Ingelheim
  • Pfizer
  • Forest Laboratories
  • Mylan
  • AstraZeneca
  • Menarini
  • Allergan
  • Almirall
  • Novartis
  • Sumitomo Dainippon Pharma
  • Meiji Holdings
  • Sosei
  • Vectura
  • SkyePharma
  • GlaxoSmithKline
  • Grupo Ferrer
  • Mitsubishi Tanabe Pharma
  • Endo International
  • Aspen Pharmacare
  • Faes Farma
  • Dong-A ST
  • Dong-A Socio Holdings
  • Hanmi Pharmaceutical
  • Abdi Ibrahim
  • Nycomed
  • Theravance Biopharma
  • Pearl Therapeutics
  • PARI Medical Holding
  • Elevation Pharmaceuticals
  • PDL BioPharma
  • Vernalis
  • Verona Pharma
  • Kyowa Hakko Kirin
  • MedImmune
  • Lonza

For more information about this report visit https://www.researchandmarkets.com/research/zq79m5/2018_asthma?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Asthma Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Asthma Drugs